Search Results - "Mendonza, Anisha"

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes by He, Yan‐Ling, Haynes, William, Meyers, Charles D., Amer, Ahmed, Zhang, Yiming, Mahling, Ping, Mendonza, Anisha E., Ma, Shenglin, Chutkow, William, Bachman, Eric

“…BACKGROUND There is an unmet need for a safer and more effective treatment for obesity. This study assessed the effects of licogliflozin, a dual inhibitor of…”
Get full text

Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial by He, YanLing, Schofield, Jül, Mahling, Ping, Mendonza, Anisha E., Hinder, Markus

“…Treatment with licogliflozin, a dual sodium‐glucose co‐transporter (SGLT)1/2‐inhibitor, is associated with increased stool frequency and loose stools,…”
Get full text

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study by Harrison, Stephen A., Manghi, Federico Perez, Smith, William B., Alpenidze, Diana, Aizenberg, Diego, Klarenbeek, Naomi, Chen, Chi-Yi, Zuckerman, Eli, Ravussin, Eric, Charatcharoenwitthaya, Phunchai, Cheng, Pin-Nan, Katchman, Helena, Klein, Samuel, Ben-Ari, Ziv, Mendonza, Anisha E., Zhang, Yiming, Martic, Miljen, Ma, Shenglin, Kao, Sheena, Tanner, Sandra, Pachori, Alok, Badman, Michael K., He, YanLing, Ukomadu, Chinweike, Sicard, Eric

“…Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is…”
Get full text

Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans by Wang-Lakshman, Lydia, Mendonza, Anisha E., Huber, Roland, Walles, Markus, He, YanLing, Jarugula, Venkateswar

“…Absorption, metabolism, and excretion (AME) of licogliflozin, a sodium-glucose co-transporters (SGLTs) 1 and 2 inhibitor, were studied in male rats, dogs, and…”
Get full text

Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2, in patients with chronic kidney disease: A randomized trial by He, YanLing, Pachori, Alok, Chen, Ping, Ma, Shenglin, Mendonza, Anisha E., Amer, Ahmed, Marbury, Thomas C., Hinder, Markus

“…Aim To investigate the glucosuric, renal and haemodynamic effects of licogliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2…”
Get full text

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study by Kanter, Julie, Mennito, Sarah, Nair, Santosh M., Manwani, Deepa, Kutlar, Abdullah, Shah, Nirmish, Keefe, Deborah, Madhamshetty, Hariprasad, Nassin, Michele, Reshetnyak, Evgeniya, Mendonza, Anisha E., Liles, Darla

“…Background: Crizanlizumab is a novel inhibitor of P-selectin, a key player in multicellular adhesion and inflammatory signaling, that leads to vaso-occlusion…”
Get full text

Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study by Risinger, Robert, Bhagwagar, Zubin, Luo, Feng, Cahir, Matthew, Miler, Laura, Mendonza, Anisha E., Meyer, Jeffrey H., Zheng, Ming, Hayes, Wendy

“…Rationale BMS-820836, a novel triple monoamine reuptake inhibitor, is an experimental monotherapy for sufferers of major depressive disorder who have had an…”
Get full text

Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep) by Mogi, Muneto, Mendonza, Anisha E., Chastain, James, Demirs, John T., Medley, Quintus G., Zhang, Qin, Papillon, Julien P. N., Yang, Junzheng, Gao, Yan, Xu, YongYao, Stasi, Kalliopi

“…PurposeTo evaluate the pharmacology and toxicology of SAF312, a transient receptor potential vanilloid 1 (TRPV1) antagonist. MethodsTRPV1 expression in human…”
Get full text

The Concentration of Cyclosporine Metabolites Is Significantly Lower in Kidney Transplant Recipients With Diabetes Mellitus by AKHLAGHI, Fatemeh, DOSTALEK, Miroslav, FALCK, Pål, MENDONZA, Anisha E, AMUNDSEN, Rune, GOHH, Reginald Y, ASBERG, Anders

“…Diabetes mellitus is prevalent among kidney transplant recipients. The activity of drug metabolizing enzymes or transporters may be altered by diabetes leading…”
Get full text

Blood and Plasma Pharmacokinetics of Ciclosporin in Diabetic Kidney Transplant Recipients by Mendonza, Anisha E., Gohh, Reginald Y., Akhlaghi, Fatemeh

“…Background and objectives: Long-term diabetes mellitus may affect the absorption, distribution and metabolism of immunosuppressive agents used after organ…”
Get full text

Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry by MENDONZA, Anisha E, GOHH, Reginald Y, AKHLAGHI, Fatemeh

“…Salivary levels of the immunosuppressive agent, mycophenolic acid (MPA), may provide a convenient and noninvasive method for drug monitoring. An analytical…”
Get full text

Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry by Patel, Chirag G., Mendonza, Anisha E., Akhlaghi, Fatemeh, Majid, Oneeb, Trull, Andrew K., Lee, Terry, Holt, David W.

“…Two simple, sensitive and reproducible methods for determination of total mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) as well as unbound MPA…”
Get full text

Tacrolimus in diabetic kidney transplant recipients : Pharmacokinetics and application of a limited sampling strategy by MENDONZA, Anisha E, ZAHIR, Hamim, GOHH, Reginald Y, AKHLAGHI, Fatemeh

“…The effect of diabetes mellitus on the pharmacokinetics of tacrolimus is not well characterized. We have compared tacrolimus 12-hour steady-state…”
Get full text

S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2‐YEAR DATA FROM THE PHASE 2 SOLACE‐KIDS STUDY by Heeney1, Matthew, Rees, David, Montalembert, Mariane, Odame, Isaac, Wali, Yasser, Sayyed, Sarfaraz, Shanmuganathan Muthusamy, Velusamy, Mendonza, Anisha E., Nassin, Michele, Keefe, Deborah, Kanter, Julie

Get full text

Bioavailability of valsartan oral dosage forms by Sunkara, Gangadhar, Bende, Girish, Mendonza, Anisha E., Solar-Yohay, Susan, Biswal, Shibadas, Neelakantham, Srikanth, Wagner, Robert, Flarakos, Jimmy, Zhang, Yiming, Jarugula, Venkateswar

“…The oral bioavailability of valsartan from extemporaneous suspension and solution formulations were evaluated relative to tablet formulation in two separate…”
Get full text

Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease: Final Interim Analysis Results from the Phase 2 Solace-Adults Study by Kanter, Julie, Mennito, Sarah, Nair, Santosh M, Manwani, Deepa, Kutlar, Abdullah, Shah, Nirmish, Keefe, Deborah, Madhamshetty, Hariprasad, Reshetnyak, Evgeniya, Mendonza, Anisha E, Liles, Darla K.

“…Background: Acute painful vaso-occlusive crises (VOCs), the hallmark of sickle cell disease (SCD), are associated with chronic and potentially life-threatening…”
Get full text

Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid by Mendonza, Anisha, Hanna, Imad, Meyers, Dan, Koo, Phillip, Neelakantham, Srikanth, Zhu, Bing, Majumdar, Tapan, Rebello, Sam, Sunkara, Gangadhar, Chen, Jin

“…Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, has activity in common metabolic diseases associated with abnormal accumulation of…”
Get full text

LIK066, a Dual SGLT1/2 Inhibitor, Reduces Weight and Improves Multiple Incretin Hormones in Clinical Proof-of-Concept Studies in Obese Patients With or Without Diabetes by HE, YANLING, HAYNES, WILLIAM G., MEYERS, CHARLES D., AMER, AHMED, ZHANG, YIMING, MAHLING, PING C., MENDONZA, ANISHA E., MA, SHENGLIN, CHUTKOW, WILLIAM, BACHMAN, ERIC S.

“…Background: LIK066 is a potent dual inhibitor of SGLT1/2 (IC50: 20.6 and 0.58 nM for SGLT1 and SGLT2). We studied mechanistic effects of dual SGLT1/2…”
Get full text

Abstract 456: Assessment of Pharmacokinetic Drug Interaction between LCZ696 and Metformin by Mendonza, Anisha, Akahori, Mizuki, Langenickel, Thomas, Swan, Therese, Pal, Parasar, Sunkara, Gangadhar, Chandra, Priyamvada

“…Abstract only Objective: LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) being developed for the treatment of cardiovascular…”
Get full text

Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects by Gan, Lu, Jiang, Xuemin, Mendonza, Anisha, Swan, Therese, Reynolds, Christine, Nguyen, Joanne, Pal, Parasar, Neelakantham, Srikanth, Dahlke, Marion, Langenickel, Thomas, Rajman, Iris, Akahori, Mizuki, Zhou, Wei, Rebello, Sam, Sunkara, Gangadhar

“…LCZ696 is a novel angiotensin receptor neprilysin inhibitor in development for the treatment of cardiovascular diseases. Here, we assessed the potential for…”
Get full text